Can Fite Biopharma Stock Analysis

CANF Stock  USD 3.90  0.26  7.14%   
Can Fite Biopharma is undervalued with Real Value of 6.95 and Target Price of 17.33. The main objective of Can Fite stock analysis is to determine its intrinsic value, which is an estimate of what Can Fite Biopharma is worth, separate from its market price. There are two main types of Can Fite's stock analysis: fundamental analysis and technical analysis.
The Can Fite stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Can Fite's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Can Stock Analysis Notes

The company has price-to-book (P/B) ratio of 1.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Can Fite Biopharma recorded a loss per share of 3.0. The entity last dividend was issued on the 10th of May 2019. The firm had 1:10 split on the 9th of January 2023. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Can-Fite Biopharma operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 8 people. For more info on Can Fite Biopharma please contact Pnina Fishman at 972 3 924 1114 or go to https://www.canfite.com.

Can Fite Biopharma Investment Alerts

Can Fite Biopharma is way too risky over 90 days horizon
Can Fite Biopharma appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 743 K. Net Loss for the year was (7.63 M) with profit before overhead, payroll, taxes, and interest of 810 K.
Can Fite Biopharma currently holds about 12.77 M in cash with (8.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Can Fite Biopharma has a frail financial position based on the latest SEC disclosures
Latest headline from globenewswire.com: Join Can-Fites Exclusive Live Investor Webinar and QA Session on August 8

Can Fite Biopharma Upcoming and Recent Events

4th of April 2024
Upcoming Quarterly Report
View
6th of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Can Largest EPS Surprises

Earnings surprises can significantly impact Can Fite's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-11-26
2018-09-30-0.06-0.1344-0.0744124 
2022-11-25
2022-09-30-1.1-0.90.218 
2022-08-25
2022-06-30-1.05-0.80.2523 
View All Earnings Estimates

Can Fite Environmental, Social, and Governance (ESG) Scores

Can Fite's ESG score is a quantitative measure that evaluates Can Fite's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Can Fite's operations that may have significant financial implications and affect Can Fite's stock price as well as guide investors towards more socially responsible investments.

Can Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.17 M.

Can Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.76)(0.80)
Return On Capital Employed(1.03)(1.08)
Return On Assets(0.76)(0.80)
Return On Equity(1.22)(1.28)

Management Efficiency

Can Fite Biopharma has return on total asset (ROA) of (0.5315) % which means that it has lost $0.5315 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4249) %, meaning that it created substantial loss on money invested by shareholders. Can Fite's management efficiency ratios could be used to measure how well Can Fite manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.8. The current Return On Capital Employed is estimated to decrease to -1.08. At this time, Can Fite's Other Current Assets are most likely to increase significantly in the upcoming years. The Can Fite's current Total Current Assets is estimated to increase to about 10.3 M, while Non Currrent Assets Other are forecasted to increase to (107.7 K).
Last ReportedProjected for Next Year
Book Value Per Share 1.47  1.39 
Tangible Book Value Per Share 1.47  1.39 
Enterprise Value Over EBITDA(0.63)(0.66)
Price Book Value Ratio 1.50  1.43 
Enterprise Value Multiple(0.63)(0.66)
Price Fair Value 1.50  1.43 
Enterprise Value5.1 M4.9 M
The analysis of Can Fite's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Can Fite's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Can Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin
(11.83)
Beta
0.687
Return On Assets
(0.53)
Return On Equity
(1.42)

Technical Drivers

As of the 18th of July 2024, Can Fite shows the Mean Deviation of 3.84, downside deviation of 4.61, and Risk Adjusted Performance of 0.1203. Can Fite Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Can Fite Biopharma maximum drawdown, and the relationship between the information ratio and downside variance to decide if Can Fite Biopharma is priced correctly, providing market reflects its regular price of 3.9 per share. Given that Can Fite has jensen alpha of 0.9301, we suggest you to validate Can Fite Biopharma's prevailing market performance to make sure the company can sustain itself at a future point.

Can Fite Biopharma Price Movement Analysis

Execute Study
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Can Fite middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Can Fite Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Can Fite Outstanding Bonds

Can Fite issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Can Fite Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Can bonds can be classified according to their maturity, which is the date when Can Fite Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Can Fite Predictive Daily Indicators

Can Fite intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Can Fite stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Can Fite Corporate Filings

6K
11th of July 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
3rd of July 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
1st of July 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
28th of June 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
26th of June 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
24th of June 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
10th of June 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
7th of June 2024
Other Reports
ViewVerify

Can Fite Forecast Models

Can Fite's time-series forecasting models are one of many Can Fite's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Can Fite's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Can Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Can Fite prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Can shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Can Fite. By using and applying Can Stock analysis, traders can create a robust methodology for identifying Can entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(10.27)(10.79)
Operating Profit Margin(11.03)(11.58)
Net Loss(10.27)(10.79)
Gross Profit Margin 0.88  0.78 

Current Can Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Can analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Can analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
17.33Strong Buy2Odds
Can Fite Biopharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Can analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Can stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Can Fite Biopharma, talking to its executives and customers, or listening to Can conference calls.
Can Analyst Advice Details

Can Stock Analysis Indicators

Can Fite Biopharma stock analysis indicators help investors evaluate how Can Fite stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Can Fite shares will generate the highest return on investment. By understating and applying Can Fite stock analysis, traders can identify Can Fite position entry and exit signals to maximize returns.
Begin Period Cash FlowM
Common Stock Shares Outstanding4.3 M
Total Stockholder Equity6.2 M
Property Plant And Equipment Net81 K
Cash And Short Term Investments8.9 M
Cash4.3 M
Accounts Payable427 K
Net Debt-4.2 M
50 Day M A2.6388
Total Current LiabilitiesM
Other Operating Expenses8.9 M
Non Current Assets Total81 K
Stock Based Compensation261 K

Complementary Tools for Can Stock analysis

When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges